Heechul Nam, Ji Won Han, Soon Kyu Lee, Hyun Yang, Hae Lim Lee, Pil Soo Sung, Myeong Jun Song, Jung Hyun Kwon, Jeong Won Jang, U-Im Chang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jin Mo Yang, Hee Yeon Kim
BACKGROUND AND AIM: Our study evaluated the outcomes of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB). We assessed viral and biochemical responses as well as changes in the estimated glomerular filtration rate (eGFR) and bone mineral density (BMD). METHODS: This retrospective multicenter study included CHB patients who achieved virologic response (VR) (HBV DNA < 20 IU/mL) while on TDF and were subsequently switched to TAF between April 2018 and October 2021...
May 1, 2024: Journal of Gastroenterology and Hepatology